naproxen has been researched along with nortriptyline in 15 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (nortriptyline) | Trials (nortriptyline) | Recent Studies (post-2010) (nortriptyline) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 2,289 | 517 | 327 |
| Protein | Taxonomy | naproxen (IC50) | nortriptyline (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.016 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.0032 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.347 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.095 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.17 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.027 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.366 | |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | 1.9 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1.95 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.082 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.17 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.047 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.1015 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.019 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.171 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.539 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.0032 | |
| Histamine H2 receptor | Homo sapiens (human) | 2.334 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.273 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.051 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.016 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 1.019 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.17 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.013 | |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.17 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3 | |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.17 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.05 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.179 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.136 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 7 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.554 | |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | 10 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.678 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Forster, HS | 1 |
| Arvidsson, T | 1 |
| Theodoridis, G | 1 |
3 review(s) available for naproxen and nortriptyline
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for naproxen and nortriptyline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Naproxen reversal of nortriptyline-induced orthostatic hypotension.
Topics: Aged; Depressive Disorder; Female; Humans; Hypotension, Orthostatic; Naproxen; Nortriptyline | 1989 |
Effects of drug-protein binding on trace enrichment of drugs in blood plasma on short precolumns.
Topics: Amitriptyline; Blood Proteins; Chemical Phenomena; Chemistry, Physical; Humans; Hydrogen-Ion Concentration; Naproxen; Nortriptyline; Pharmaceutical Preparations; Phosphoric Acids; Protein Binding; Serum Albumin | 1988 |
Application of solid-phase microextraction in the investigation of protein binding of pharmaceuticals.
Topics: Binding, Competitive; Chromatography, High Pressure Liquid; Ciprofloxacin; Haloperidol; Humans; Kinetics; Naproxen; Nortriptyline; Paclitaxel; Pharmaceutical Preparations; Protein Binding; Quinidine; Quinine; Serum Albumin; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Ultrafiltration | 2006 |